HomeAI · summaries
Storia in 3 fonti
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its…
- ·
fiercepharma.com
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker
- ·
benzinga.com
Johnson & Johnson Hits Goal With IMAAVY In Rare Blood Disorder - Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority Review.
- ·
EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage
In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought to the world stage a reminder of its status as a…